Palatin Technologies, Inc.

PTN Healthcare Biotechnology

In the quarter to June 2026, revenue fell 14.1%, EPS fell 276.3% and free cash flow grew 34.2%, each against the same quarter a year earlier.

6.02 0.47 −7.24%
Market cap
$11.6M
P/E
0.0×
Fwd P/E
0.2×
Dividend yield
—
F-score
n/a
Altman Z
−67.72
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 4.19 0.00
P/S ratio
0.58 3.44 5.15 2.31
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(4.75) (8.13) (15.43) (11.34)
P/B ratio
19.43 3.41 6.43 4.56
EV/Sales
0.49 2.18 4.39 1.75
EV/EBITDA
0.00 0.00 0.00 0.00
EV/FCF
(0.41) (1.55) (3.88) (1.70)
Current Ratio
1.02 2.76 5.04 4.61
Net Debt/EBITDA
(0.27) 1.98 6.50 1.70
Debt/Equity
0.00 0.00 0.00 0.00
Earnings Yield
(96.07%) (29.06%) 23.89% (27.52%)
Free Cash Flow Yield
(207.90%) (40.76%) (21.99%) (44.55%)
Free Cash Flow per Share
(1.67) (1.90) (1.14) (0.95)
Book value per Share
0.41 4.51 2.71 2.37
Free Cash Flow
(1.62) (4.82) (4.46) (2.69)
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 30 Sep 2026